FDA Brief

Warning letters Biologics

FDA warning letter to

Adnan Dahdul, MD

High riskIssued Mar 12Posted May 26Office of Compliance and Biologics Quality

FDA warns clinical investigator Dr. Adnan Dahdul over consent, eligibility and record failures in a biologics study.

What happened

FDA inspected Dr. Dahdul's clinical study site in Springfield, Massachusetts, from May 6 to June 20, 2024, and gave him a Form FDA 483 (a list of inspection observations) at the end. FDA found that at least three subjects had study procedures done before consent (permission) was signed, that subjects with conditions the protocol excluded were enrolled, and that some subjects got the wrong or an expired study drug. FDA also found source records with no staff signatures and undocumented changes, and it rejected his written responses as inadequate.

What FDA found

  1. For at least three subjects, study procedures such as pregnancy tests, vital signs and blood draws were done before informed consent (the subject's signed agreement to take part) was obtained.

    21 CFR 312.60 and 21 CFR 50.20
  2. Subjects with medical histories or active conditions the protocol excluded, such as bipolar disorder, schizoaffective disorder, schizophrenia and drug or alcohol abuse, were enrolled anyway.

    21 CFR 312.60
  3. For at least two subjects, a complete medical history was not taken at the first visit as the protocol required, and the missing conditions were only recorded months later.

    21 CFR 312.60
  4. In at least three cases the study drug was given incorrectly: two subjects received a kit other than the one assigned at randomization, and one subject was dosed with an expired drug.

    21 CFR 312.60
  5. For the first 196 subjects enrolled, source records did not show which staff member made the entries, with no initials, signatures or other identification.

    21 CFR 312.62(b)
  6. Source data did not match the electronic data system, pages were missing and unexplained, times were changed without explanation, and one subject's death was recorded as cardiac arrest when the death certificate listed fentanyl and ethanol intoxication.

    21 CFR 312.62(b)

What FDA wants

Within 15 business days, Dr. Dahdul must write to FDA explaining how he will fix the lack of investigator oversight and staff supervision, and how he will verify data accuracy and reconcile source records with the electronic data system, with documented examples. If he cannot meet the deadline, he must explain why and give a completion date.

Who should pay attention

  • sponsors and contract research organizations relying on data from this investigator site
  • other clinical investigators and research site staff running biologic trials
  • institutional review boards and research compliance staff overseeing human subject protection

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Stephen J. Fallon, Ph.D.

    FDA warns clinical investigator Stephen J. Fallon, Ph.D. over consent and record failures in an HIV self-test study.

    High risk
  2. Pratik Doshi, M.D. / Alembic Pharmaceuticals Ltd.

    FDA warned investigator Dr. Pratik Doshi at Alembic's Vadodara site that a bioequivalence study consent form wrongly said nothing was experimental.

    High risk
  3. Sourav K. Mishra, M.D. / All India Institute of Medical Sciences

    FDA warned clinical investigator Dr. Sourav K. Mishra at AIIMS Bhubaneswar over a doxorubicin liposome bioequivalence study that broke protocol and consent rules.

    High risk
  4. Mukesh B. Chandre, M.D., MBBS/Ashirwad Hospital & Research Centre

    FDA warned clinical investigator Dr. Mukesh Chandre over informed consent failures in a doxorubicin liposome bioequivalence study.

    High risk